Category: Investigations

Embark Technology, Inc. (EMBK) Criticized as Being “More Bark than Bite”   Robbins LLP is investigating Embark Technology, Inc. (NASDAQ: EMBK) to determine whether certain

Applied Therapeutics, Inc. (APLT) Holds Submission of New Drug Application for AT-007 Applied Therapeutics Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular

Laboratory Corporation of America Holdings’ (LH) Prenatal Tests May be Inaccurate On January 1, 2022, an article from the New York Times called into question

Meta Materials Inc. (MMAT) Misled Investors Regarding its Business Prospects   A shareholder filed a class action on behalf of all persons who purchased or

Natera, Inc.’s (NTRA) Prenatal Tests May be Inaccurate Up to 85% of the Time On January 1, 2022, an article from the New York Times

Clarivate Plc (CLVT) Made Financial Misstatements On December 27, 2021, Clarivate disclosed in a filing with the U.S. Securities and Exchange Commission that “[o]n December

Zillow Group, Inc. (Z, ZG) Misled Investors Regarding its Ability to Forecast Home Prices for its Zillow Offers Business A class action was filed on

Ipsidy Inc. (AUID) Is Accused of Misstating its Sources of Revenue Robbins LLP is investigating the officers and directors of Ipsidy Inc. (NASDAQ: AUID) for

Revance Therapeutics, Inc. (RVNC) Misled Investors Regarding FDA Approval of its Lead Drug Candidate A class action was filed on behalf of all persons and